Latest Headlines

Latest Headlines

Sanofi launches Zika vaccine R&D; effort

As the global alarm continues to sound about the Zika virus, Sanofi said on Tuesday that it's getting involved. In doing so, it became the first major pharmaceutical company to get involved in the Zika vaccine race, launching a program to develop a jab just after receiving the first regulatory approvals for its dengue shot.

UPDATED: NewLink wins $26.1M in government funding to advance Ebola vaccine

NewLink Genetics won a total of $26.1 million in funding to further the development of its candidate Ebola vaccine from the DOD's Defense Threat Reduction Agency and HHS' BARDA in the span of just over a week. The company has licensed the research, development and manufacturing of the jab to Merck.

Merck takes its Ebola vaccine to Phase III in Sierra Leone

In the latest development in the race for an Ebola vaccine, Merck and partner NewLink have taken their candidate to late-stage trials in Sierra Leone, the companies announced Tuesday.

GlaxoSmithKline and Merck Ebola vaccines succeed in Phase II Liberian trials

Two Ebola vaccines, one developed by the NIH and GlaxoSmithKline and the other by Merck and NewLink, have sailed through Liberian trials and, based on the results, may now advance to Phase III trials.

NewLink nets $20M Ebola milestone from Merck

NewLink's Ebola vaccine tie-up with Merck continues to pay off.